# Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma

> **NCT07686744** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jian Lin** · enrollment: 8 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Advanced
- Recurrent
- Refractory

## Interventions

- **DRUG:** Personalized Neoantigen Polyepitope Peptide Vaccine

## Key facts

- **NCT ID:** NCT07686744
- **Lead sponsor:** Jian Lin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686744, "Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*